切换至 "中华医学电子期刊资源库"
高级检索
中华乳腺病杂志(电子版)

中华乳腺病杂志(电子版) ›› 2022, Vol. 16 ›› Issue (01) : 1 -5. doi: 10.3877/cma.j.issn.1674-0807.2022.01.001

所属专题： 总编推荐；

专题笔谈

中国乳腺癌临床研究进展
李芷君1, 徐兵河1,†()   
  1. 1. 100021　北京，国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院内科
  • 收稿日期:2021-07-23 出版日期:2022-02-01
  • 通信作者: 徐兵河

Clinical researches of breast cancer in China

Zhijun Li1, Binghe Xu1,†()   

  1. 1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
  • Received:2021-07-23 Published:2022-02-01
  • Corresponding author: Binghe Xu
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

李芷君, 徐兵河. 中国乳腺癌临床研究进展[J]. 中华乳腺病杂志(电子版), 2022, 16(01): 1-5.

Zhijun Li, Binghe Xu. Clinical researches of breast cancer in China[J]. Chinese Journal of Breast Disease(Electronic Edition), 2022, 16(01): 1-5.

中国乳腺癌患者基数大，疾病的发生、发展有其独特的临床特征，因此研发适合中国人群的药物及探索合适的治疗方式尤为重要。近1年来，中国自主研发了多种创新药物，包括细胞周期蛋白依赖性激酶4/6(CDK4/6)抑制剂达匹西利、多腺苷二磷酸核糖聚合酶(PARP)抑制剂帕米帕利、抗体-药物偶联物维迪西妥单克隆抗体(RC48-ADC)、程序性死亡配体-1(PD-L1)单克隆抗体TQB2450等，同时探索了乳腺癌的多种治疗模式，如ER低表达乳腺癌的短程内分泌治疗、三阳性(ER、PR、HER-2均阳性)乳腺癌去化疗、三阴性乳腺癌(TNBC)豁免蒽环方案、卡培他滨辅助强化治疗等，对乳腺癌的临床诊疗提供了重要的指导价值。笔者分别针对激素受体阳性乳腺癌、HER-2阳性乳腺癌以及TNBC中近1年来中国临床研究的热点问题进行探讨。

关键词: 乳腺肿瘤, 临床研究, 受体，雌激素, 受体，erbB-2, 三阴性乳腺癌

China has a large number of breast cancer patients, and the occurrence and development of the disease has unique clinical characteristics. Therefore, it is important to develop drugs and treatment methods for the Chinese population. In the past year, China has independently developed many novel drugs, including cyclin-dependent kinase (CDK) 4/6 inhibitor dalpiciclib, poly ADP-ribose polymerase (PARP) inhibitor pamiparib, antibody-drug conjugate disitamab vedotin (RC48-ADC), and programmed cell death-ligand 1 (PD-L1) monoclonal antibody TQB2450. Meanwhile, new treatment methods for breast cancer has been explored, such as short-course endocrine therapy for breast cancer with low ER expression, exemption from chemotherapy for triple positive breast cancer (ER positive, PR positive, HER-2 positive), exemption from anthracycline use for triple negative breast cancer, and capecitabine for adjuvant intensive chemotherapy, which provides important guidance for the clinical diagnosis and treatment of breast cancer. This paper discussed the hot issues of clinical research on hormone receptor positive breast cancer, HER-2 positive breast cancer and triple negative breast cancer in China.

Key words: Breast neoplasms, Clinical study, Receptors, estrogen, Receptor, erbB-2, Triple negative breast neoplasms
[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3)：209-249.
[2]
National Institutes of Health, U．S. National Library of Medicine. A similar map is available for all studies in ClinicalTrials.gov[EB/OL]. [2021-06-20].

URL    
[3]
Xu B, Zhang Q, Zhang P, et al. Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1002.
[4]
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869)：805-816.
[5]
Bartlett J, Sgroi DC, Treuner K, et al. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial[J]. Ann Oncol, 2019, 30(11)：1776-1783.
[6]
Yu KD, Cai YW, Shao ZM. De-escalation of five years adjuvant endocrine therapy duration in patients with ER-low positive (immunohistochemical 1% to 10%) early-stage breast cancer: A propensity-matched analysis from the prospectively maintained database[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.538.
[7]
Sun T, Shi YX, Cui JW, et al. A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER-2-negative breast cancer with germline BRCA mutation[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1087.
[8]
Yan M, Ouyang Q, Sun T, et al. Pyrotinib plus capecitabine for HER-2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase Ⅱ study[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1037.
[9]
Ding XW, Mo WJ, Xie XH, et al. Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase Ⅱ trial[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.574.
[10]
Yuan ZY, Huang JJ, Hua X, et al. Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER-2-positive: The sysucc-002 randomized clinical trial[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1003.
[11]
Zhang J, Meng YC, Wang BY, et al. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1035.
[12]
Wang JY, Liu YJ, Zhang QY, et al. RC48-ADC, a HER-2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1022.
[13]
Hu XC, Zhang J, Liu RJ, et al. Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors[EB/OL]. [2021-11-11]. https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.1024.
[14]
Xue C, Yao HR, Lin Y, et al. Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1042.
[15]
Zheng FC, Du F, Wang YS, et al. Efficacy of epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes as adjuvant chemotherapy in triple-negative breast cancer: 8.1 years median follow-up on a randomized clinical trial[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.529.
[16]
Li J, Yu K, Pang D, et al. Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase Ⅲ trial[J]. J Clin Oncol, 2020, 38(16)：1774-1784.
[17]
Yuan ZY, Hua X, Li WZ, et al. Predict the benefit of metronomic capecitabine maintenance in early-stage triple-negative breast cancer: Results from the SYSUCC-001 study[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.521.
[18]
Wang JY, Xu BH, Sun T, et al. A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1074.
[19]
Chen L, Shao ZM, Wang ZH, et al. Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1007.
[20]
Li DD, Tao ZH, Wang BY, et al. Apatinib plus vinorelbine versus vinorelbine for advanced triple-negative breast cancer with failed first or second-line treatment: The NAN trial[EB/OL]. [2021-06-20]. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.1075.
[1] 郏亚平, 曾书娥. 含鳞状细胞癌成分的乳腺化生性癌的超声与病理特征分析[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 844-848.
[2] 唐玮, 何融泉, 黄素宁. 深度学习在乳腺癌影像诊疗和预后预测中的应用[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 323-328.
[3] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[4] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[5] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[6] 伍秋苑, 陈佩贤, 邓裕华, 何添成, 周丹. 肠道微生物在乳腺癌中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 362-365.
[7] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[8] 周婉丽, 钱铮, 李喆. 槐耳在乳腺癌免疫治疗中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 369-371.
[9] 熊倩, 罗凤. 乳腺癌患者术后康复现状与对策的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 372-374.
[10] 贺敬龙, 尚宏喜, 郝敏, 谢伟, 高明宏, 孙炜, 刘安庆. 重度类风湿关节炎患者行多关节置换术的临床手术疗效[J]. 中华关节外科杂志(电子版), 2023, 17(06): 860-864.
[11] 马伟强, 马斌林, 吴中语, 张莹. microRNA在三阴性乳腺癌进展中发挥的作用[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 111-114.
[12] 姚宏伟, 魏鹏宇, 高加勒, 张忠涛. 不断提高腹腔镜右半结肠癌D3根治术的规范化[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 1-4.
[13] 栗艳松, 冯会敏, 刘明超, 刘泽鹏, 姜秋霞. STIP1在三阴性乳腺癌组织中的表达及临床意义研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 52-56.
[14] 晏晴艳, 雍晓梅, 罗洪, 杜敏. 成都地区老年转移性乳腺癌的预后及生存因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 636-638.
[15] 李智铭, 郭晨明, 庄晓晨, 候雪琴, 高军喜. 早期乳腺癌超声造影定性及定量指标的对比研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 639-643.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号